Meeting
2015 Genitourinary Cancers Symposium
AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Emmanuel S. Antonarakis
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
Emmanuel S. Antonarakis , Changxue Lu , Yan Chen , Brandon Luber , Hao Wang , Mary Nakazawa , Angelo M. De Marzo , William B. Isaacs , Rosa Nadal , Channing Judith Paller , Samuel R. Denmeade , Michael Anthony Carducci , Mario A. Eisenberger , Jun Luo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 138)
DOI
10.1200/jco.2015.33.7_suppl.138
Abstract #
138
Poster Bd #
A4
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
AR-V7 in Asian patients with metastatic CRPC: A multinational, multicentre study.
First Author: Hui Shan Tan
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES).
First Author: Karim Fizazi
Poster
2019 Genitourinary Cancers Symposium
Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Edmond Michael Kwan
Poster
2014 ASCO Annual Meeting
A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).
First Author: Daniel Peter Petrylak